Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | NMT2 | O60551 | 2/20 | 0.31 |
| ▸ | NMT1 | P30419 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22994768 | 0.89 | KDM4E (0.32) | KDM4EMAPTHPGDNPSR1MEN1 | |
| SCHEMBL21912065 | 0.88 | KDM4E (0.34) | KDM4EMAPTHPGDNPSR1MEN1 | |
| SCHEMBL19637446 | 0.86 | KDM4E (0.36) | KDM4EMAPTHPGDNPSR1MEN1 | |
| SCHEMBL22994676 | 0.85 | KDM4E (0.34) | KDM4EMAPTHPGDNPSR1MEN1 | |
| SCHEMBL22994752 | 0.84 | KDM4E (0.35) | KDM4EMAPTHPGDNPSR1MEN1 | |
| SCHEMBL19637079 | 0.81 | HTT (0.32) | KDM4EMAPTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL22994841 | 0.77 | KDM4E (0.38) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21896269 | 0.76 | CHRNB2 (0.36) | — | |
| SCHEMBL19637432 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL25019973 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020055756-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055760-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055755-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |